-
Prioritizing High-Risk HCC: Safety of STRIDE in Asian Patients with Child-Pugh B and Vp4 — SIERRA Update
Editor’s Note: At a recent GI oncology symposium, Prof. Jung Yong Hong (Samsung Medical Center, South Korea) presented safety results from the Phase 3b SIERRA study, focusing on Asian patients…
-
Landmark Analysis Reveals New Dimensions of CheckMate 9DW: IMAEs May Predict Enhanced Benefit of Nivo+Ipi in Unresectable HCC
Editor’s Note: In an oral presentation selected by the ESMO Asia Scientific Committee, Dr. David Tai (Singapore) presented updated subgroup analyses from the Phase III CheckMate 9DW study, examining the…
-
Bridging the Resistance Gap: The 2025 GI Immunotherapy Roadmap
Editor’s Note: Despite the success of immune checkpoint inhibitors (ICIs) in GI tumors, immune resistance and the immunosuppressive tumor microenvironment (TME) remain major barriers. At a recent symposium, Prof. Kohei…
-
ASH China Voice | Prof. Yanli Zhao / Dr. Wei Zhao: Efficacy and Strategic Insights of Allogeneic Transplantation in AML and Aplastic Anemia
The 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando from December 6 to 9, 2025, showcasing the latest global advances in hematology. Multiple studies…
-
ASH China Voice | First Affiliated Hospital of USTC: Award-Winning Innovations Tackling Key Challenges in Hematologic Malignancies
From December 6–9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, bringing together leading experts worldwide to present the latest breakthroughs in…
-
ASH25 China Voice | Dr. Yishan Ye: Haploidentical Transplantation Shows Superior Outcomes for MRD-Positive AML in CR
Previous collaborative studies between the European Society for Blood and Marrow Transplantation (EBMT) and Prof. He Huang’s team have demonstrated that haploidentical hematopoietic stem cell transplantation (HAPLO-HSCT) can confer clinical…
-
ASH China Voice | Prof. Ou Bai: Optimizing Lymphoma Management—From PCNS-DLBCL Treatment Strategies to Virus-Associated Risk Control
Optimizing PCNS-DLBCL Treatment R-MT Induction and the Role of Consolidation or Maintenance Therapy At ASH 2025, Prof. Bai’s team reported favorable outcomes using rituximab plus high-dose methotrexate and thiotepa (R-MT)…
-
ASH China Voice | Prof. Yajing Zhang: Exploring Frontiers and Synergistic Innovation—A Multidimensional and Strategic Vision for CAR-T Therapy
The 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando from December 6 to 9, 2025, bringing together the latest global advances in hematologic research and clinical practice. At this year’s meeting, four studies led by Prof. Yajing Zhang from Beijing Gobroad Boren Hospital were accepted, including one oral presentation.
Connecting Medical Expertise through Media